MarginsXMarginsX
Home › Markets › EVFM

Evofem Biosciences, Inc. (EVFM)

EVFM is quoted over the counter, not listed on an exchange. Evofem Biosciences, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 13, 2026
$0.0060
0.0% on the day
1-year return
-40.0%
Market cap
$795K
Nano cap. From the Nov 13, 2026 close × 132.5M shares (10-Q cover page, Nov 9, 2026)
P/E and P/S
Net loss over the period · 0.0×
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerEVFM, quoted over the counter
SEC CIK0001618835
OTC Markets tierOTCID (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressSan Diego, CA
Incorporated inDE

Warning signs

Cash runway
7.2 months
$285K cash at June 30, 2026
Share count, 1 year
+4.6%
2025-11-12 to 2026-11-09 · +1135.1% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern. 2."
10-Q 2026-11-13
Cash and burn$285K cash; operating cash flow -$118K a quarter.Report 2026-06-30
Shares outstanding132,530,081 (2026-11-09); 126,685,925 a year earlier; 10,730,210 three years earlier.Cover page 2026-11-09
Reverse splits, 3 years1; latest on 2025-11-26Source 2025-11-26
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBPM LLP, Sacramento, California, United StatesPCAOB Form AP 2026-03-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$2.6M-$11.0M-$3.1M$285K$362K$18.0M10-Q 2026-08-14
Q1 2026
2026-03-31
$899K-$5.5M$2.3M$1.5MNo debt tags$20.2M10-Q 2026-05-15
Q4 2025
2025-12-31
$9.6M$2.8M$31K$578K$147K$20.2M10-K 2026-03-11
Q3 2025
2025-09-30
$5.0M-$1.6M$336K$840K$291K$17.7M10-Q 2025-11-13
Q2 2025
2025-06-30
$4.8M-$1.8M-$2.9M$748K$383K$17.3M10-Q 2026-08-14
Q1 2025
2025-03-31
$845K$956K$560K$221KNo debt tags$16.6M10-Q 2026-05-15
Q4 2024
2024-12-31
$7.1M-$3.0M-$2.4M$741K$135K$19.4M10-K 2026-03-11
Q3 2024
2024-09-30
$4.5M-$2.4M-$459K$722K$268K$17.1M10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32023-08-14
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEF 14A2025-10-29

Source: SEC EDGAR submissions feed, 804 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier